John Martin, MD
Family Medicine · Edmond, OKNPI 1376619866
Payments from drug & device makers
Across 166 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$1K
- AbbVie$951
- Pfizer$573
- Novo Nordisk$525
- Amgen$475
- GSK$422
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,451100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 40 | $1,289 |
| AbbVie(2 entities) | 13 | $951 |
| Pfizer | 16 | $573 |
| Novo Nordisk | 9 | $525 |
| Amgen | 7 | $475 |
| GSK | 8 | $422 |
| Lilly USA, LLC | 18 | $356 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| Otsuka America Pharmaceutical, Inc. | 8 | $249 |
| Eisai Inc. | 3 | $244 |
| Corcept Therapeutics | 2 | $235 |
| Novartis | 7 | $213 |
| Johnson & Johnson | 3 | $205 |
| Amarin Pharma, Inc. | 2 | $196 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $174 |
| AstraZeneca(2 entities) | 2 | $135 |
| Kowa Pharmaceuticals America, Inc. | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $115 |
| Rhythm Pharmaceuticals, Inc. | 1 | $115 |
| Radius Health, Inc. | 5 | $114 |
| Althera Pharmaceuticals LLC | 1 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Pharmacosmos Therapeutics Inc. | 1 | $78 |
| E.r. Squibb & Sons, L.L.C. | 2 | $72 |
| Boehringer Ingelheim | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,454 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 343 | $107,897 |
| JardianceEmpagliflozin | 121 | $60,584 |
| NuplazidPimavanserin Tartrate | 13 | $32,007 |
| TrulicityDulaglutide | 30 | $29,692 |
| XareltoRivaroxaban | 47 | $26,522 |
| JanuviaSitagliptin Phosphate | 34 | $19,412 |
| OzempicSemaglutide | 16 | $17,266 |
| MyrbetriqMirabegron | 16 | $6,910 |
| LinzessLinaclotide | 11 | $4,458 |
| Gabapentin | 246 | $4,455 |
| Divalproex Sodium | 121 | $4,413 |
| Tamsulosin Hcl | 205 | $4,215 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 106 | $4,188 |
| Ropinirole Hcl | 96 | $3,918 |
| Levothyroxine Sodium | 347 | $3,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $573 | $107,897343 claims |
| Boehringer IngelheimJardiance | $36 | $60,584121 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,289 | $32,00713 claims |
| Lilly USA, LLCTrulicity | $356 | $29,69230 claims |
| Johnson & JohnsonXarelto | $205 | $26,52247 claims |
| Novo NordiskOzempic | $525 | $17,26616 claims |
| AbbVieLinzess | $951 | $4,45811 claims |
| GSKArexvy | $422 | $3,67412 claims |
| Sanofi-aventis U.S. LLCLantus | $100 | $1,83216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.